A detailed history of Boston Research & Management Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Boston Research & Management Inc holds 52,238 shares of ABBV stock, worth $9.36 Million. This represents 2.42% of its overall portfolio holdings.

Number of Shares
52,238
Previous 52,413 0.33%
Holding current value
$9.36 Million
Previous $8.99 Million 14.75%
% of portfolio
2.42%
Previous 2.27%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$163.84 - $199.33 $28,672 - $34,882
-175 Reduced 0.33%
52,238 $10.3 Million
Q2 2024

Aug 13, 2024

SELL
$154.79 - $180.76 $96,588 - $112,794
-624 Reduced 1.18%
52,413 $8.99 Million
Q1 2024

May 14, 2024

SELL
$159.82 - $182.1 $114,271 - $130,201
-715 Reduced 1.33%
53,037 $9.66 Million
Q4 2023

Feb 12, 2024

BUY
$137.6 - $154.97 $81,872 - $92,207
595 Added 1.12%
53,752 $8.33 Million
Q3 2023

Nov 13, 2023

SELL
$133.59 - $154.65 $7,347 - $8,505
-55 Reduced 0.1%
53,157 $7.92 Million
Q2 2023

Aug 01, 2023

BUY
$132.51 - $164.9 $3,975 - $4,947
30 Added 0.06%
53,212 $7.17 Million
Q1 2023

May 10, 2023

SELL
$144.61 - $166.54 $77,510 - $89,265
-536 Reduced 1.0%
53,182 $8.48 Million
Q4 2022

Feb 13, 2023

SELL
$138.31 - $165.87 $160,301 - $192,243
-1,159 Reduced 2.11%
53,718 $8.68 Million
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $29,123 - $33,402
-217 Reduced 0.39%
54,877 $7.37 Million
Q2 2022

Aug 11, 2022

SELL
$137.62 - $174.96 $172,300 - $219,049
-1,252 Reduced 2.22%
55,094 $8.44 Million
Q1 2022

May 12, 2022

SELL
$131.98 - $163.75 $305,797 - $379,408
-2,317 Reduced 3.95%
56,346 $9.13 Million
Q4 2021

Feb 10, 2022

SELL
$107.43 - $135.93 $20,948 - $26,506
-195 Reduced 0.33%
58,663 $7.94 Million
Q3 2021

Nov 10, 2021

BUY
$106.4 - $120.78 $65,968 - $74,883
620 Added 1.06%
58,858 $6.35 Million
Q3 2021

Nov 10, 2021

BUY
$106.4 - $120.78 $16,492 - $18,720
155 Added 0.27%
58,238 $6.3 Million
Q2 2021

Aug 11, 2021

SELL
$105.21 - $117.21 $16,307 - $18,167
-155 Reduced 0.27%
58,083 $6.54 Million
Q1 2021

May 11, 2021

BUY
$102.3 - $112.62 $59,334 - $65,319
580 Added 1.01%
58,238 $6.3 Million
Q4 2020

Feb 09, 2021

BUY
$80.49 - $108.67 $73,809 - $99,650
917 Added 1.62%
57,658 $6.18 Million
Q3 2020

Nov 09, 2020

SELL
$85.91 - $100.83 $125,514 - $147,312
-1,461 Reduced 2.51%
56,741 $4.97 Million
Q2 2020

Aug 10, 2020

BUY
$73.37 - $98.18 $19,883 - $26,606
271 Added 0.47%
58,202 $5.71 Million
Q1 2020

May 08, 2020

SELL
$64.5 - $97.79 $50,116 - $75,982
-777 Reduced 1.32%
57,931 $4.41 Million
Q4 2019

Feb 07, 2020

SELL
$72.13 - $90.25 $21,711 - $27,165
-301 Reduced 0.51%
58,708 $5.2 Million
Q3 2019

Nov 12, 2019

BUY
$62.98 - $75.72 $187,995 - $226,024
2,985 Added 5.33%
59,009 $4.47 Million
Q2 2019

Aug 07, 2019

BUY
$65.7 - $83.98 $73,584 - $94,057
1,120 Added 2.04%
56,024 $4.07 Million
Q1 2019

May 07, 2019

BUY
$77.14 - $90.79 $268,832 - $316,403
3,485 Added 6.78%
54,904 $4.42 Million
Q4 2018

Feb 06, 2019

BUY
$77.85 - $96.01 $461,650 - $569,339
5,930 Added 13.04%
51,419 $4.74 Million
Q3 2018

Nov 13, 2018

SELL
$88.91 - $98.84 $73,795 - $82,037
-830 Reduced 1.79%
45,489 $4.3 Million
Q2 2018

Jul 30, 2018

SELL
$89.78 - $106.23 $21,996 - $26,026
-245 Reduced 0.53%
46,319 $4.29 Million
Q1 2018

May 09, 2018

SELL
$92.01 - $123.21 $356,538 - $477,438
-3,875 Reduced 7.68%
46,564 $4.41 Million
Q4 2017

Feb 09, 2018

SELL
$89.56 - $98.21 $217,630 - $238,650
-2,430 Reduced 4.6%
50,439 $4.88 Million
Q3 2017

Nov 09, 2017

BUY
$69.85 - $89.22 $3.69 Million - $4.72 Million
52,869
52,869 $4.7 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $317B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Boston Research & Management Inc Portfolio

Follow Boston Research & Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boston Research & Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Boston Research & Management Inc with notifications on news.